What do we know about antiretroviral treatment of HIV in women?

Antiviral Therapy

Volumn 18, Issue SUPPL.2, 2013, Pages 27-34

  Monforte, Antonella D'Arminio ^a   Anderson, Jane ^b   Olczak, Anita ^c  

^a SAN PAOLO HOSPITAL   (Italy)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; METHADONE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AREA UNDER THE CURVE; BIRTH DEFECT; BODY FAT DISTRIBUTION; BONE DENSITY; CD4+ T LYMPHOCYTE; COGNITIVE DEFECT; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL STRESS; EUROPE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER DISEASE; LYMPHOCYTE COUNT; METABOLIC DISORDER; NAUSEA; OSTEOPOROSIS; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SEX DIFFERENCE; SOCIAL ASPECT; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; VAGINA DISCHARGE; VIRUS LOAD; WOMEN'S HEALTH;

ANTI-RETROVIRAL AGENTS; COMORBIDITY; EUROPE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; MALE; MEDICATION ADHERENCE; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; WOMEN'S HEALTH; WOMEN'S HEALTH SERVICES;

EID: 84879614774     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2647     Document Type: Review

References (59)

1. UNAIDS. UNAIDS report on the global AIDS epidemic 2010. (Accessed 26 April 2012.) Available from http://www.unaids.org/GlobalReport/documents/ 20101123-GlobalReport-full-en.pdf
2. European AIDS Clinical Society. Clinical management and treatment of HIV-infected adults in Europe, version 6.0. (Accessed 22 February 2012.) Available from http://www.europeanaidsclinicalsociety.org/images/stories/EACS- Pdf/eacsguidelines-v6-english.pdf
3. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2011. (Accessed 22 February 2012.) Available from http://aidsinfo.nih.gov/contentfiles/ AdultandAdolescentGL.pdf
4. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9:563-608.
5. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
6. de Ruiter A, Mercey D, Anderson J, et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9:452-502.
7. Department of Health and Human Services. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States, 2011. (Accessed 20 February 2012.) Available from http://aidsinfo.nih.gov/ contentfiles/PerinatalGL.pdf
8. de Ruiter A, Taylor G P, Clayden P, et al. Guidelines for the management of HIV infection in pregnant women, 2012. (Accessed 7 February 2013.) Available from http://www.bhiva.org/documents/Guidelines/Treatment/2012/ 120430PregnancyGuidelines.pdf
9. Navér L, Albert J, Belfrage E, et al. Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2010. Scand J Infect Dis 2011; 43:411-423.
10. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Recommendations for a public health approach (2010 version). (Accessed 7 February 2013.) Available from http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html
11. World Health Organization. UNAIDS. WHO / UNAIDS Policy Statement: Ensuring equitable access to antiretroviral treatment for women, 2004. (Accessed 7 February 2013.) Available from http://www.who.int/hiv/pub/advocacy/en/ policy%20statement-gwh.pdf
12. Stengaard AR, Lazarus JV, Donoghoe MC, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for women and children in the WHO European Region 2002-2006. AIDS Care 2009; 21:893-902.
13. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med 2007; 4:106-119.
14. Burger D, van der Heiden I, La Porte C, et al. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 2006; 61:148-154.
15. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol 2006; 62:552-559.
16. Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 2008; 13:901-907.
17. von Hentig N, Babacan E, Lennemann T, et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62:579-582.
18. Taylor S, Davies S. Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:335-343.
19. Kwara A, Delong A, Rezk N, et al. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008; 46:719-725.
20. Eron J, Jr., Yeni P, Gathe J, Jr., et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476-482.
21. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
22. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
23. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
24. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50:367-374.
25. Soon G, Min M, Struble K, Chan-Tack K, Murray J, Birnkrant D. Meta-analysis of efficacy outcomes for treatment-naive and experienced HIV-infected women in randomized controlled clinical trials (RCTs) (2000-2008). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. 12-15 September 2010, Boston, MA, USA. Abstract H-1812.
26. Currier J, Averitt BD, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 2010; 153:349-357.
27. Cohen CJ, Molina J-M, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: pooled results from the Phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60:33-42.
28. Martorell C, Mayer CA, Ribera E, et al. Week 96 safety and efficacy by gender and race subgroups in treatment-naive HIV-1-infected patients in the Phase III ECHO and THRIVE trials. Annual Meeting of the Infectious Diseases Society of America. 20-23 October 2011, Boston, MA, USA. Abstract 404.
29. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-456.
30. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011; 204:1191-1201.
31. Smith K Y, Tierney C, Daar ES, et al. Association of race/ethnicity and sex with outcomes in ACTG A5202. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Poster 536.
32. Squires KE, Johnson M, Yang R, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 2011; 66:363-370.
33. Barber TJ, Geretti AM, Anderson J, et al. Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antivir Ther 2011; 16:805-814.
34. Murri R, Lepri AC, Phillips AN, et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I. Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34:184-190.
35. Powderly WG. The three ages of antiretroviral therapy - its evolution and the emergence of long-term safety concerns. Eur Infect Dis 2007; 1:19-25.
36. Nicastri E, Leone S, Angeletti C, et al. Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review. J Antimicrob Chemother 2007; 60:724-732.
37. Johnson M, Squires K, Hosey T, et al. Gender-based differences in antiretroviral-naive patients treated with ritonavir-boosted protease inhibitors: 96 week results from the CASTLE study. 12th European AIDS conference. 11-14 November 2009, Cologne, Germany. Abstract PE7.3/8.
38. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31 Suppl 3:S140-S144.
39. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr 2003; 34:58-61.
40. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32:124-129.
41. Mazhude C, Jones S, Murad S, Taylor C, Easterbrook P. Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS 2002; 16:1566-1568.
42. Antiretroviral Pregnancy Registry. Interim report, June 2012. (Accessed 7 February 2013.) Available from http://www.apregistry.com/forms/interim-report. pdf
43. Haberl A, Reitter A. How does HIV affect the reproductive choices of women of childbearing age? Antivir Ther 2013; 18 Suppl 2:35-44.
44. Blanco JR, Caro AM, Perez-Cachafeiro S, et al. HIV infection and aging. AIDS Rev 2010; 12:218-230.
45. Dominguez S, Branco T, Haruperi T. Considerations for the long-term management of women living with HIV in Europe. Antivir Ther 2013; 18 Suppl 2:45-52.
46. Spire B, Carrieri P, Garzot MA, L'henaff M, Obadia Y. Factors associated with efavirenz discontinuation in a large community-based sample of patients. AIDS Care 2004; 16:558-564.
47. Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23:1519-1529.
48. Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci 2010; 32:575-580.
49. Cingolani A, Torti L, Pinnetti C, et al. Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 2010; 24:2408-2412.
50. Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66:2107-2111.
51. Santoro N, Fan M, Maslow B, Schoenbaum E. Women and HIV infection: the makings of a midlife crisis. Maturitas 2009; 64:160-164.
52. Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. Treatment responses in antiretroviral treatment-naive premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. Clin Infect Dis 2009; 49:473-476.
53. Kempf MC, Pisu M, Dumcheva A, Westfall AO, Md JM, Saag MS. Gender differences in discontinuation of antiretroviral treatment regimens. J Acquir Immune Defic Syndr 2009; 52:336-341.
54. Roberts KJ, Mann T. Barriers to antiretroviral medication adherence in HIV-infected women. AIDS Care 2000; 12:377-386.
55. Sayles JN, Wong MD, Cunningham WE. The inability to take medications openly at home: does it help explain gender disparities in HAART use? J Womens Health (Larchmt) 2006; 15:173-181.
56. Turner BJ, Laine C, Cosler L, Hauck WW. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users. J Gen Intern Med 2003; 18:248-257.
57. Sordo del Castillo L, Ruiz-Perez I, Olry de Labry Lima A. Biological, psychosocial, therapeutic and quality of life inequalities between HIV-positive men and women - a review from a gender perspective. AIDS Rev 2010; 12:113-120.
58. Guaraldi G, Murri R, Orlando G, et al. Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. HIV Clin Trials 2003; 4:99-106.
59. Rueda S, Park-Wyllie LY, Bayoumi AM, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev 2006; 3:CD001442.